IA
HEPA

IFP Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

IFP Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$1K – 3842
2022
Q4 		– Hold
0
– – – 4361
2022
Q3 		– Hold
0
– – – 4566
2022
Q2 		– Hold
0
– – – 4341
2022
Q1 		– Hold
0
– – – 4340
2021
Q1 		– Sell
-5
Closed -$11K – 3090
2020
Q4 		$11K Buy
+5
New +$13K ﹤0.01% 2032

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

IFP Advisors's HEPA Position: Q1 2023 in Review

IFP Advisors held its Hepion Pharmaceuticals (HEPA) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3842.

IFP Advisors first reported a position in HEPA in Q4 2020 and has held it in 1 quarter since. The position peaked at $11K in Q4 2020. 26 funds tracked by Wall St. Rank hold HEPA as of Q1 2023.

  • IFP Advisors held 0 shares of Hepion Pharmaceuticals worth $0 as of Q1 2023.
  • IFP Advisors left its Hepion Pharmaceuticals share count unchanged in Q1 2023.
  • Hepion Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q1 2023, its #3842 holding.
  • IFP Advisors first reported a position in Hepion Pharmaceuticals in Q4 2020 and has held it in 1 quarter since.
  • IFP Advisors's Hepion Pharmaceuticals position peaked at $11K in Q4 2020.
  • 26 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2023.

Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.